Transcatheter or Surgical Treatment of Aortic-Valve Stenosis

Stefan Blankenberg1, Moritz Seiffert1, Reinhard Vonthein1

  • 1From the Department of Cardiology and the Center for Population Health Innovation, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf (S. Blankenberg, M.S., P.C., N.D., R.T., A.Z.), German Center for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung [DZHK]) partner site Hamburg-Kiel-Lübeck (S. Blankenberg, M.S., P.C., J.C., N.D., I.E., S.E., D.F., I.R.K., H.R., R.T.), and the Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg (H.R.), Hamburg, the Department of Cardiology and Angiology, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum (M.S.), the Institute of Medical Biometry and Statistics, University of Lübeck (R.V., I.R.K.), the Departments of Cardiology, Angiology, and Intensive Care Medicine (I.E.) and Cardiovascular Surgery (S.E.), University Hospital of Schleswig-Holstein, Lübeck, the Department of Cardiology III-Adult Congenital and Valvular Heart Disease, University Hospital Münster, Müster (H.B.), the Departments of Thoracic and Cardiovascular Surgery (S. Bleiziffer) and General and Interventional Cardiology-Angiology (T.K.R.), Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, University Clinic of Cardiac Surgery (M.A.B.) and the Department of Internal Medicine (H.T.), Heart Center Leipzig at Leipzig University (M.A.B., H.T.), and Leipzig Heart Science (H.T.) and the Department of Cardiology at University Hospital Leipzig (A.H.), Leipzig, the Departments of Cardiac Surgery (Y.-H.C.) and Cardiology (W.-K.K.), Kerckhoff Clinic, Bad Nauheim, Medical Clinic I, the Department of Cardiology and Angiology, University of Giessen and Marburg (W.-K.K.), and Campus Kerckhoff and Medical Clinic I, University of Giessen (C. Hamm), Giessen, the Departments of Cardiovascular Surgery (J.C.) and Internal Medicine III (D.F.), University Hospital of Schleswig-Holstein, Kiel, Clinic for Cardiovascular Surgery, University Heart Center Freiburg-Bad Krozingen, University Clinic Freiburg, and the Faculty of Medicine, Albert Ludwigs University Freiburg (M.C.), and the Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg (F.-J.N., D.W.), Freiburg, the Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital (N.F.), DZHK partner site Heidelberg-Mannheim (N.F., M. Karck), and the Department of Cardiac Surgery, University Hospital Heidelberg (M. Karck), Heidelberg, the Departments of Cardiac Surgery (C. Hagl) and Cardiology (S.M.), University Hospital Munich, Ludwig Maximilians University Munich, DZHK partner site Munich Heart Alliance (C. Hagl, M. Krane, S.M., E.X.), and the Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine and Health (M. Krane), and the Department of Cardiology, German Heart Center Munich, Technical University of Munich (E.X.), Munich, DZHK partner site Rhine-Main, Rhine-Main (C. Hamm, W.-K.K., T.W.), the Departments of Cardiac Surgery (U.K.) and Internal Medicine and Cardiology (A.L.), Heart Center Dresden, University of Technology Dresden, Dresden, the Departments of Cardiology, Angiology, and Intensive Care Medicine (U.L.) and Cardiothoracic and Vascular Surgery (V.F.), Deutsches Herzzentrum der Charité, Charité University Medicine Berlin (U.L., V.F.), and DZHK partner site Berlin (U.L., V.F.), Berlin, the Departments of Internal Medicine II (L.S.M.) and Cardiothoracic Surgery (C.S.), University Medical Center Regensburg, Regensburg, and the Department of Cardiac and Vascular Surgery, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main (T.W.) - all in Germany; the Division of Cardiac Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT (M. Krane); Cardio-CARE, Medizincampus Davos, Davos (A.Z., S. Blankenberg), and the Department of Health Sciences and Technology, ETH Zurich, Translational Cardiovascular Technology, Zurich (V.F.) - both in Switzerland; and the School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa (A.Z.).

Abstract

Related Concept Videos

Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
686
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
478